2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 5.932

Change

+0.07 (+1.21)%

Market Cap

USD 0.49B

Volume

0.08M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.60 (+1.20%)

USD 450.46B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.19 (+1.23%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.24 (+0.94%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.31 (+1.15%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.27 (+1.14%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-0.52 (-0.34%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+2.54 (+1.86%)

USD 104.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.38 (+0.89%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.60 (+1.21%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+10.20 (+2.07%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.95% 43% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.95% 43% F 46% F
Trailing 12 Months  
Capital Gain 9.22% 47% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.22% 47% F 51% F
Trailing 5 Years  
Capital Gain 33.41% 54% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.41% 52% F 54% F
Average Annual (5 Year Horizon)  
Capital Gain 6.74% 67% D+ 64% D
Dividend Return 6.74% 65% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.73% 41% F 52% F
Risk Adjusted Return 45.78% 62% D 64% D
Market Capitalization 0.49B 68% D+ 60% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.